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Cannabis sativa contains many related compounds known as
phytocannabinoids. The main psychoactive and nonpsychoac-
tive compounds are 9-tetrahydrocannabinol (THC) and can-
nabidiol (CBD), respectively. Much of the evidence for clinical
efficacy of CBD-mediated antiepileptic effects has been from
case reports or smaller surveys. Themechanisms forCBD’s anti-
convulsant effects are unclear and likely involve noncannabi-
noid receptor pathways. CBD is reported to modulate several
ion channels, including sodium channels (Nav). Evaluating the
therapeutic mechanisms and safety of CBD demands a richer
understanding of its interactions with central nervous system
targets. Here, we used voltage-clamp electrophysiology of HEK-
293 cells and iPSCneurons to characterize the effects of CBDon
Nav channels. Our results show that CBD inhibits hNav1.1–1.7
currents, with an IC50 of 1.9–3.8 M, suggesting that this inhi-
bition could occur at therapeutically relevant concentrations. A
steep Hill slope of 3 suggested multiple interactions of CBD
with Nav channels. CBD exhibited resting-state blockade,
became more potent at depolarized potentials, and also slowed
recovery from inactivation, supporting the idea that CBD bind-
ing preferentially stabilizes inactivated Nav channel states. We
also found that CBD inhibits other voltage-dependent currents
from diverse channels, including bacterial homomeric Nav
channel (NaChBac) and voltage-gated potassium channel sub-
unit Kv2.1. Lastly, the CBD block of Nav was temperature-de-
pendent, with potency increasing at lower temperatures. We
conclude thatCBD’smodeof action likely involves 1) compound
partitioning in lipid membranes, which alters membrane fluid-
ity affecting gating, and 2) undetermined direct interactions
with sodium and potassium channels, whose combined effects
are loss of channel excitability.
The cannabis plant is composed of over 100 compounds
known as phytocannabinoids (1). Among these phytocannabi-
noids, CBD,2 is of great interest because of its lack of potency on
CB1 and CB2 receptors that are thought to mediate psychotro-
pic activity. Interactions with these receptors by yet another
cannabinoid, THC, at submicromolar concentrations cause the
well known cannabis effects (2). Recently, reports of the use of
CBD as an anticonvulsant agent have been rapidly increasing
(3); however, to date, there is no consensus on a well defined
mode of action for the CBD-mediated antiepileptic effects.
Because CBD has a lower affinity for the endocannabinoid
receptors than THC (4), several studies suggest that the anti-
convulsant effects of THC and CBD in maximal electroshock
(ED50 120 mg/kg, brain concentration  22 M) and pilo-
carpine models occur via different mechanisms (5, 6). Whereas
the THC activity is mostly on the CB1 receptor, the anticonvul-
sant effects of CBD are not. These findings have inspired the
growth of CB1- and CB2-independent focused research. Many
mechanisms have been proposed for the action of CBD on dif-
ferent systems. CBD acts as an agonist on humanTRP channels
(3–30 M), and specifically on TRPV1 (7, 8), which is in part
responsible for calcium channel modulation (9). CBD also
inhibits heterologously expressed Cav3.1, Cav3.2, and native
neuronal T-type voltage-gated calcium channels (10). These
low-voltage activated channels also can be blocked by other
antiepileptic drugs such as zonisamide (11). In addition to Cav
channels, CBD inhibits persistent and resurgent sodium cur-
rents generated by WT-Nav1.6 channels and the exacerbated
versions of these currents inGOF epilepsy-causingNav1.6-mu-
tants (12). A recent human clinical trial has indicated that CBD
(dosed at 20 mg/kg) is efficacious against drug-resistant sei-
zures in Dravet syndrome (3). Previous investigations of the
cannabis-mediated blockade of Nav channels have determined
that CBD (10 M) significantly decreases action potential fre-
quency in rat CA1 hippocampal neurons and Nav current den-
sity in human neuroblastoma cells and mouse cortical neurons
(13). Other studies have used dissociated hippocampal cultures
derived from embryonic day 18 rats to measure toxicity and
neuroprotective responses to CBD. These studies indicate that
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the EC50 of CBD is within the 1–4 M range while causing
neurotoxicity at 33 M (14).
The transient sodium current throughNav channels initiates
action potentials in neurons, skeletalmuscles, and cardiacmus-
cles. Any changes to the gating properties of these channels,
and subsequently the current passed through them during an
action potential, can cause extremely life-limiting conditions
that can sometimes be lethal. Both GOF and LOF in sodium
channels disrupt electrical signaling (15–18).
In the primary sodium channel isoforms of the central nerv-
ous system, Nav1.1, 1.2, 1.3, and 1.6, both GOF and LOF elicit
epilepsy syndromes (15, 19–21). These include relatively mild
epilepsies, like benign familial neonatal-infantile seizures, and
more severe forms, such asDravet syndrome (22–24) and early-
infantile epileptic encephalopathy-13 (25).
Compounds that inhibit Nav current have been used exten-
sively for clinical treatment of all of the above hyperexcitability
disorders (26). In this study, we sought to characterize, in detail,
the biophysical effects of CBD on peripheral and central nerv-
ous system sodium channel isoforms.
Results
CBD is an inhibitor of human sodium currents
Previous reports suggested thatNav currents are inhibited by
micromolar concentrations ofCBDbut lacked detailed concen-
tration-response data and defined potencies. We sought to
determine whether CBD has any selectivity across the sodium-
channel superfamily. Thus, we measured the concentration
dependence of inhibition of inactivated-state sodium channels
by CBD. Our results demonstrate that CBD inhibits hNav1.1–
1.7with lowmicromolar potency (Fig. 1,A andD). To construct
the concentration response, individual cells were exposed to
single concentrations of CBD; then normalized inhibition at
each concentration was pooled and fit with a Hill Langmuir
equation, providing IC50 and Hill slopes (Fig. 1A). Representa-
tive current traces at approximately IC50 concentrations for
each subtype tested are shown in (Fig. 1C). Interestingly, the
sodium-current inhibition has very steep Hill slopes of 2
across all subtypes (Fig. 1, A and D). This indicates that CBD
does not likely inhibit the channel currents through a 1:1 bind-
ing mechanism but instead suggests multiple interactions con-
tribute to this inhibition. Although there is some variation in
the IC50 values obtained on each subtype, the steep Hill slopes
make IC50 values extremely sensitive to small changes in con-
centration, which could account in part for this variation of
2-fold in IC50. Similar to the hNav channels, CBD also inhib-
ited themouseNav1.6 (mNav1.6) current, suggesting that these
human IC50 values hold in rodent isoforms (Fig. 1, A and D).
THC inhibition of Nav currents
The chemical structures of CBD and THC are very similar,
with the sole difference being the closure of a ring on THC as
Figure 1. CBD and THC inhibit Nav currents. A, the IC50 curves of CBD block on hNav1.1–1.7 andmNav1.6. The chemical structure of CBD is shown in the top
left corner. B, THC IC50 of hNav1.2 compared with CBD. The pulse protocols used and the chemical structure of THC are shown on the bottom right. Channels
were exposed to each compound for 20min. C, representative current traces at IC50 in each sodium channel. Traces are taken from the concentrations that are
closest to IC50. D, table of IC50 and Hill slope fitted parameters (n 3–15 cells exposed at each concentration; the S.E. values quoted are errors of the fit).
CBD inhibition of Nav currents
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opposed to a free hydroxyl group in CBD. Given that this dif-
ference is the structural basis for the functional differences
between CBD and THC, we tested THC against hNav1.2. Our
results suggest that although the potency of the sodium-current
inhibition betweenTHCandCBD is similar, theHill slope asso-
ciatedwithTHC is less steep (Fig. 1,B andD). Thismay indicate
that THC has some differences in the mechanism of sodium-
current inhibition than CBD.
CBD prevents Nav channels from opening
We next examined the effects of CBD on Nav channel acti-
vation by measuring peak channel conductance at membrane
potentials between120 and30 mV. We show the effects of
3.3 M CBD on peak sodium-current densities (Fig. 2A) and a
plot of conductance (Fig. 2B). Approximately 90% of the
sodium conductance was inhibited. The normalized conduct-
ance is plotted against membrane potential, showing that CBD
does not induce large changes in either the midpoint (V1⁄2) or
apparent valence (slope, k) of activation of the available sodium
channels (p  0.05) (Fig. 2C). Therefore, exposure to CBD at
this concentration prevents channels from conducting; how-
ever, this exposure does not alter the voltage dependence of
activation.
We next measured the voltage dependence of fast inactiva-
tion. The normalized current amplitudes at the test pulse is
shown as a function of prepulse voltages (Fig. 2D). The current
at the test pulse was inhibited by more than 90%; however,
unlike activation, the voltage dependence of steady-state fast
inactivation of the remaining current was hyperpolarized by 8.1
mV (p 0.0002). This indicates CBD increased the propensity
for channels to inactivate over the 500-ms prepulse in channels
that were not inhibited from opening from rest, suggesting that
CBD stabilizes the inactivated state of sodium channels.
It was previously shown that 1 M CBD inhibits the persis-
tent and resurgent sodium currents in form of epilepsy caused
by hNav1.6 GOFmutation, N1768D, which displays a noninac-
tivating component (12). We also found that CBD inhibits the
resurgent current induced by including 200 M 4-peptide to
the intracellular solution. Fig. 2E shows that 5MCBD inhibits
the majority of resurgent currents, which is consistent with
CBD preventing channels from opening (Fig. 2A). Next, we
sought to establish the concentration dependence of CBD inhi-
bition of the persistent current of the inactivation-deficient
N1768Dmutant.We found that persistent currentswere inhib-
ited at slightly lower concentrations than the peak currents,
suggesting there may be interactions between CBD and the
open or inactivated states over the course of a 100-ms depolar-
ization (Fig. 2F).
CBD stabilizes inactivated states of Nav channels
We used a protocol to examine state-dependent inhibition
across a range of holding potentials where channel inactivation
Figure 2. CBD effects on activation, steady-state fast inactivation (SSFI), resurgent, and persistent currents. A, conductance difference in hNav1. 1 in
vehicle and3.3MCBDconcentration (vehicle:V1⁄242.50.8, slope3.10.7,n11;CBD:V1⁄239.61.8, slope4.61.5,n5).B, averagecurrent
density of hNav1.1 in vehicle and CBD (vehicle: current density  75.3  8.9 pA/pF, n  11; CBD: current density  6.8  3.0 pA/pF, n  5). C, voltage
dependence of activation as normalized conductance plotted against membrane potential (vehicle: V1⁄241.9 0.4 mV, slope 3.6 0.4, n 7; CBD: V1⁄2
40.3 1.0 mV, slope 7.2 0.9, n 5).D, voltage dependence of SSFI as normalized current plotted against membrane potential (vehicle: V1⁄269.7
0.2 mV, slope 5.0 0.2, n 12; CBD: V1⁄277.8 0.3 mV, slope 5.8 0.3, n 5). E, resurgent current block in hNav1.6 (vehicle: resurgent density
33.9 4.8 pA/pF, n 11; CBD: resurgent density7.3 1.2 pA/pF, n 23; tetrodotoxin (TTX): resurgent density3.3 0.7 pA/pF, n 31). F, IC50 of
CBDblock of peak andpersistent currents in hNav1.6mutant (N1768D) (peak: IC50 10.0 0.7M, slope 2.0 0.4, n 3–11; persistent: IC50 6.4 1.0M,
slope 1.3 0.2, n 3–9).
CBD inhibition of Nav currents
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varies (27). We first held channels at a holding potential of
100 mV where channels are almost all in the resting state,
whereas pulsing the channels 180 times at 1Hz to allowCBD to
reach equilibrium. Then we depolarized the holding potential
by 10mV threemore times and repeated the pulse train at each
voltage (Fig. 3A). We show the fractional block of sodium cur-
rents from the last pulse (180th) from each holding potential
(Fig. 3B). Fig. 3C shows a plot of the inverse of the apparent IC50
fit with a four-state binding model that used parameters
obtained from the Boltzmann fit of the voltage dependence of
steady-state fast inactivation. This established that the appar-
ent potency is directly related to the proportion of inactivated
channels at different holding potentials. Our results demon-
strate that CBD inhibits the sodium current from both rest and
inactivated states; however, the potency of CBD is 10-fold
greater for inhibiting inactivated compared with resting states
(Fig. 3C).
To assess the time dependence and degree of stabilization of
the inactivated state, we thenmeasured the recovery from inac-
tivation of hNav1.6 in the presence of 3.7 M CBD (Fig. 1A).
This was done after depolarizing prepulse durations of 300 ms
and 10 s, from a holding potential of120 mV. These prepulse
durations correspond to inactivation recovery from fast and
slow inactivated states, respectively. The mean normalized
recovery following the prepulse in CBD and control conditions
were plotted and fit with a biexponential function (Fig. 3,D and
E). The Slow and fraction of the recovery fit with Slow are plot-
ted in Fig. 3F, which shows that CBD increases the fraction of
recovery that is slow and the time constant of the slow compo-
nent of recovery from inactivation from 300 ms to 10 s. This
indicates that CBD slows the recovery from inactivation, sup-
porting the hypothesis that CBD stabilizes the inactivated
states (Fig. 3, D–F).
CBD potency is increased at lower temperatures
Binding kinetics are typically responsive to changes in tem-
perature, with higher temperatures increasing the rates of com-
pound equilibration. To further investigate the mode of CBD
interaction with sodium channels, we measured the observed
rates of equilibration (time constant observed, obs) of inhibi-
tion by fitting single exponential decays to inhibition of cur-
rents at three different temperatures.We examined the kinetics
at concentrations above the IC50 to ensure a clear inhibition
signal window to define the obs (Fig. 4, A–C). Channels were
held at45mVand pulsed at 1Hz following a recovery pulse to
150mV for 60ms, and CBDwas rapidly applied to the cells at
different concentrations (Fig. 4A). The fraction of inhibition
was normalized against the response in vehicle and plotted
against the time elapsed after CBD addition, which was set at
t  0. The inhibition was then fit with a single exponential
function to obtain  and plotted against concentration. We
show that obs saturated at aminimumwith increasing concen-
trations, counter to the prediction of a single two-state ligand-
binding reaction, which predicts a continually increasing obs
with increasing compound concentrations (Fig. 4D). This sug-
gests a rate-limiting step in the inhibitory pathway that is not
Figure 3. State-dependent inhibition of Nav current by CBD and effects on recovery from inactivation. A, pulse protocol showing 180 pulses run at 1 Hz
at eachholdingpotential and representative current traces.B, CBDpotency at four holdingpotentials at pulse 180 (3min) (IC50:100mV 12.7 1.0M,90
mV10.30.5M,80mV6.70.4M,70mV2.90.6M;n2–6).C, apparentKd at different voltageswaswell fitwith a four-statemodel invoking
different potencies for resting and inactivated-state block.D and E, recovery from inactivation in 3.7MCBD at: 300ms (vehicle (Veh): Fast 0.00173 s, Slow
0.0688 s, n 35; CBD: Fast 0.00654 s; Slow 0.516 s; n 3) and 10 s (vehicle: Fast 0.0715 s, Slow 0.696 s, n 33; CBD: Fast 0.272 s; Slow 8.72 s; n
3). F, the slow components of recovery from inactivation in vehicle and CBD at 300 ms and 3 s are shown on the left y axis, and the fraction of slow to fast
component of recovery from inactivation is shown on the right y axis.
CBD inhibition of Nav currents
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dependent on the concentration of CBD in bulk solution as
would be expected for binding to a specific inhibitory site on the
channel. Interestingly, the kinetics of CBD inhibition were also
found to bemore rapid at cooler temperatures (Fig. 4D). This is
the opposite of what is expected for a classic inhibitor in a
two-state binding model, where the binding and unbinding
rate constants, kon and koff, are intrinsically temperature-de-
pendent. These results further suggest that CBD does not
inhibit conductance through a direct interaction with a sin-
gle specific binding site on the channel. We also found that
the potency of CBD is increased at the lower temperatures
(Fig. 4, E and F).
CBD does not inhibit via interactions at the classic
local-anesthetic pore-binding site
BecauseCBD inhibition shares a characteristic of classic pore
blockers (preference for the inactivated state), we created a
pore mutation in the local-anesthetic receptor site in hNav1.1
(F1763A) to determine whether the CBD potency was affected.
The Phe1763 residue is part of a well established binding site for
many of the most common local anesthetics, including tetra-
caine (TTC) (28). To avoid any impacts on potency being
caused by the shifts in stability of inactivation in this mutant
(WT-hNav1.1 inactivation V1⁄2  62.0  0.4 mV, slope 
7.2  0.4, n  3; F1763A inactivation V1⁄2  49.3  0.1 mV,
slope  6.4  0.1, n  17), we measured inhibition from a
holding potential of45 mV where both channels were50%
inactivated. To validate the F1763A-mutant channels, we also
measured the potency of TTC and compared the results against
WT-hNav1.1, which showed a drop in potency (Fig. 5A). For
CBD, the F1763A-mutant channels only caused a slight drop
in potency of 2-fold (Fig. 5B). Molecular docking using a
homology model of hNav1.1 based on the eukaryotic cock-
roach cryo-EM structure (Navpas) (Fig. S1A) suggested that
CBD may in fact bind close to Phe1763. This suggests that
Phe1763 is not a primary determinant of CBD inhibition but
does not rule out the possibility that CBD may interact with
other pore residues.
To determine whether CBD could also inhibit other nonhu-
manNav channels, we tested it on the bacterial homomericNav
channel (NaChBac) (Fig. 5C). Interestingly, we found that
NaChBac is also blocked by CBD, although with a slightly
greater potency (Fig. 5C). Unlike mammalian Nav channels,
NaChBac does not inactivate quickly (29). We hypothesized
that if the previously observed state dependence of CBD block
in hNav channels depends upon the fast-inactivation process,
then NaChBac should not show such a state dependence. The
potency measured at 100 and 55 mV suggests that state
dependence also exists in NaChBac; moreover, this effect may
be even more pronounced than in hNav channels (Fig. 5D).
This may implicate that CBD is not dependent upon, or selec-
tive among, different modes of Nav inactivation.
Our findings in the homotetramericNaChBac raise the ques-
tion of whether CBD might also inhibit voltage-gated potas-
sium channels, which are also homotetrameric. Our results
Figure4. Lower temperatures increasekinetics andpotencyofCBD inhibitory effects.A–C, the kinetics of CBDblock at 20, 28, and33 °C at 50. 0, 25.0, 12.5,
and 6.3M (20 °C: 6.3M 51.0 0.6 s, 12.5M 42.2 0.3 s, 25.0M 21.6 0.4 s, 50.0M 23.3 0.3 s; 28 °C: 6.3M 162.6 0.9 s, 12.5M 87.7
0.2 s, 25.0M 42.8 0.1 s, 50.0M 30.4 0.4 s; 33 °C: 6.3M 299.0 9.5 s, 12.5M 137.0 0.5 s, 25.0M 79.2 0.3 s, 50.0M 84.1 0.3 s, n
10–14). The variability at the lower concentration of 6.3M at 33 °C is larger because of the slowing of CBD effect. D, time constants associated with the plots
atA–C. E, IC50 at thenoted temperatures (IC50 (M): 20 °C2.10.1, 28 °C3.40.1, 33 °C4.70.2,n2–11), the slope factor is fixed at 3.4. F, relationship
of CBD potency as a function of temperature.
CBD inhibition of Nav currents
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indicate that CBD also inhibits the Kv2.1 current. Current
traces are shown (Fig. 5E). These findings, along with the pre-
vious reports of CBDmodulation of calcium-channel currents,
support the idea that CBD is a polypharmacological inhibitor of
voltage-dependent ionic currents (10).
CBD does not alter trafficking
Because CBD nonspecifically inhibits voltage-dependent
currents, we sought to establish whether incubation of CBD
could affect the channel trafficking to the cell surface over the
time scale of our voltage-clamp experiments. To address this
question, we assessed membrane-channel distribution in cells
incubated overnight with CBD. The results indicate that over-
night incubation in 5 M CBD does not alter sodium channel
trafficking and therefore would not affect trafficking on time
scales of the voltage-clamp experiments (	20min of exposure)
(Fig. S1, B–D).
CBD inhibits Nav currents in h-iPSC neurons
To determine whether our observations in HEK cells trans-
late to native neuronal voltage-dependent currents, we mea-
sured the effects of CBD on human iPSC neurons. First, we
established that potency established with manual patch-clamp
methodology, using continuous perfusion of compound, corre-
lated with Qube data by measuring the potency of sodium-
current inhibition of HEK cells expressing hNav1.2. Fig. 6A
shows the mean normalized concentration response plot,
which gave an IC50 value similar to theQube value for hNav1.2.
The slightly increased potency in the manual assay can be
explained by the temperature dependence data (Fig. 4), because
manual voltage clampwas performed at20 °C (room temper-
ature), and the Qube IC50 values were established at 28 °C (Fig.
1A). Consistent with our previous results in HEK cells, both the
neuronal sodium and potassium currents were blocked 50%
by 1 M CBD as shown by the representative families of cur-
rent traces in Fig. 6 (D and E). CBD also caused a hyperpo-
larization of 16 mV in the steady-state inactivation in the
remaining available Nav channels in iPSCs (p  0.0031),
which was similar to the shifts observed in hNav1.1 in HEK
cells (Figs. 2D and 6B). We also measured the rate time con-
stant of open-state fast inactivation at 20 mV, which did
not differ significantly before and after CBD perfusion (p 
0.05) (Fig. 6C).
CBD reduces neuronal excitability in a Hodgkin–Huxleymodel
of cortical neuron
To test the effect of IC50 concentrations of CBD on neuronal
excitability, we used amodified version of theHodgkin–Huxley
model to simulate a cortical neuron’s excitability (30, 31). In the
CBD condition, the sodium and potassium conductances were
reduced by 50%. The activation and inactivation V1⁄2 and slopes
were taken from the results shown in (Fig. 2, C and D). In our
simulations, the channels were given a series of stepwise cur-
rent injections with increasing intensities at each step for 100
ms. Each 100-ms step was followed by a 50-ms recovery period
in which no current injection was applied (Fig. 7A). Our results
Figure 5. CBDblock of F1763Amutant, NaChBac, and Kv2.1. A, TTC block of hNav1.1 (hNav1.1, IC50 1.6 0.1M, slope 0.7 0.03; Phe
1763, IC50 44.1
M)with andwithout the F1763Amutation. B, F1763A causes a slight decrease in CBDpotency in hNav1.1 (hNav1.1: IC50 2.5 0.2M, slope 2.0 0.2, n
2–6; F1763A: IC50 4.8 0.2M, slope 4.1 0.6, n 3–811 cells exposed at each concentration). C, shows a comparison of the CBD inhibition of hNav1.6,
NaChBac, and Kv2.1 (hNav1.6: IC50 3.0 0.1M, slope 3.1 0.2, n 2–6; NaChBac: IC50 1.5 0.2M, slope 2.8 0.9, n 1–4; Kv2.1: IC50 3.7 0.8
M, slope1.10.2,n1–511 cells exposed at each concentration).D, shows the state-dependent block ofNaChBac tested at55 and100mV (100mV:
IC50 1.5 0.2M, slope 2.8 0.9, n 1–4;55mV: IC50 0.24 0.05M, slope 2.8 0.9, n 1–311 cells exposed at each concentration). E, current
traces associated with the channels shown in C.
CBD inhibition of Nav currents
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suggest that the peak amplitude of the first action potential in
CBD is smaller than vehicle. This is consistent with the reduc-
tion of peak sodiumconductance caused byCBD. Furthermore,
in the CBD condition we observed that threshold for the first
action potential after depolarization was reduced (Fig. 7B). The
overall effect of CBD on the action potential morphology is
that at all current injection intensities, CBD reduces the
number of action potentials, leading to a net loss of excitabil-
ity. These results are consistent with previous studies using
current clamp recordings and may in part theoretically
explain the reported efficacy of CBD in treating conditions
including epilepsy and pain (32).
Figure 6. CBD inhibits human iPSCneuronal Nav andKv currents.A, concentration-response relationship for CBD inhibition of hNav1.2 channels obtained
usingmanual patch clamp (IC50 1.3 0.1M, slope 2.1 0.4, n 3–6). B, plot of normalized SSFI after a 100ms prepulse before (V1⁄250.0 0.4 mV,
slope 6.4 0.4, n 3) and after (V1⁄266.1 0.7mV, slope 8.1 0.6, n 3) perfusion.C, open-state fast-inactivation time constants shownon log scale
on the yaxis at20mV for vehicles (20mV: 1.30.1ms,n3) andCBD (20mV: 1.30.4ms,n3) in iPSCneurons.Dand E, representative current-voltage
relationship recorded from iPSC neurons with a KF based internal solution before 1 M perfusion of CBD (D) and after perfusion (E). Insets in the panel are
zoomed-in view of currents at the test pulse used to assess availability.
Figure 7. CBD reduces excitability in an action-potential model and schematic representation of CBD’s mode of action. A, simulation of the effects of
CBDon action potentialmorphology over a series of increasing current injection intensities. B, zoomed-in simulation of action potentials from the first interval
shown in A. C, proposed mode of action of CBD involving interactions with both the membrane, resting and inactivated sodium channels.
CBD inhibition of Nav currents
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Discussion
CBD has a weak affinity for CB receptors; thus, its anticon-
vulsant properties are attributed to modulations of other tar-
gets, including ion channels. Our study suggests that the Nav
channel family is among the possible ion channel targets of
CBD.
Our results in this study suggest that CBD as a sodium-chan-
nel inhibitor is nonselective; therefore, we performed some of
our experiments on single sodium-channel subtypes, including
the temperature dependence and channel-trafficking assays.
We believe that because of the nonspecific nature of the inter-
actions, the results obtained from single subtypes will be gen-
eralizable to the whole sodium-channel superfamily. This idea
is supported by the consistencies we observed between HEK
cells that express only a single sodium-channel subtype, and
iPSCneurons, which host several sodium-channel subtypes in a
native environment.
Mechanisms of sodium-current inhibition
The initial results obtained from the selectivity experiments
on hNav channels suggested that CBD is indeed a sodium-cur-
rent inhibitor. However, this inhibition is relatively nonselec-
tive in nature and has a steep average Hill slope, suggesting
multiple interactions. Like CBD,we found that THC also inhib-
its hNav1.2, albeit with a less steep Hill slope. Our results indi-
cated that CBD prevents the activation of sodium channels
from rest while also stabilizing the inactivated states of these
channels without altering the voltage dependence of activation.
This inhibition has similarities to that reported for amphiphilic
compounds (33, 34). It is suggested that amphiphilic com-
pounds tend to localize at the solution–bilayer interface. This
occurrence is made possible by having the polar group of the
amphiphile residing at the interface with the hydrophobic
region, which then gets inserted into the core of the bilayer.
This partitioning into the lipid bilayer alters the biophysical
properties of the membrane by reducing stiffness, changing
phase preference and curvature. The net effect of these altera-
tions to the membrane is an increased preference for the bilay-
er-embedded Nav channel in its inactivated state (34).
The similarity of CBD to amphiphiles, along with the multi-
modal interaction relationship between this compound and the
voltage-dependent sodium currents suggested three potential
mechanisms culminating in inhibition: 1) multiple direct inter-
actions between CBD and Nav channels, 2) CBD alteration of
membrane biophysical properties, or 3) a combination of direct
interactions with Nav channels and changes in the membrane
fluidity.
Evidence for CBD effects on sodium channels through altering
membrane fluidity
Contrary to what is expected for classic pseudo–second
order bimolecular blocking scheme, CBD inhibition curves dis-
played a Hill slope of 3, and compound was fastest to equili-
brate and most potent at lower temperatures, indicating that
CBD does not follow a classic blocking scheme (Fig. 4). One
potential explanation for the decreased potency at 33 °C is that
higher temperatures increase the thermal fluctuations of the
sodium channels, which become faster, and consequently, it
becomes harder for CBD to find interaction sites that may
reside in thermally volatile regions of the structure. A second
potential explanation is that because the fluidity of themembrane
changes as a function of temperature (35), higherCBDconcentra-
tions are required to have the same reduction of stiffness at 33 °C
where the membrane is more fluid than at lower temperatures,
and the relative reduction in stiffness is more pronounced.
Evidence for direct binding of CBD to the channels to cause
inhibition
Theobservation of an inactivated-state preference,which is a
characteristic of Nav pore blocking local anesthetics, led us to
investigate the CBDblock of a hNav1.1mutant (F1763A)with a
mutation in the local-anesthetic pore-binding site. We found
that CBD’s inhibitory effects were minimally affected in the
F1763Amutants. This suggests that binding at this site is not via
similar interactions to local anesthetics (28, 36), although
molecular docking supports the possibility that CBD could
interact in the pore of hNav1.1.
We found that CBD also inhibits a nonmammalian sodium
channel, NaChBac, and the voltage-gated potassium channel,
Kv2.1. Interestingly, the CBD block of NaChBac was slightly
more potent than the mammalian orthologs. This increased
potency might be due to the presence of 4-fold symmetry in
these channels, and thus, the four-time repeating of a domain
that may be involved in inhibition. Indeed, the equivalent Phe
residue in the pore of homotetrameric NaChBac that contrib-
utes to local-anesthetic binding (37) (Phe200) is repeated four
times, asopposed to the singlePhe1763 in themonomerichNav1.1,
where the F1763A mutation in Nav1.1 induced a small drop in
potency. These results offer some support to the hypothesis that,
in addition to alteringmembraneproperties,CBDmight alsohave
direct interactions with Nav channels that alter conductance.
Additionally, our observation that membrane Nav channel distri-
bution was unchanged in cells after a 24-h incubation with CBD
suggested there were no effects on trafficking.
CBD inhibits heterologously expressed and native hNav
currents
To assess whether the observed CBD inhibitory effects on
voltage-dependent currents in HEK cells could be replicated in
the native neuronal environment, we assessed inhibition of cur-
rents in iPSC neurons and saw significant inhibition of both
Nav andKv currents (Fig. 5). The potency was comparable with
the effects seen in HEK cells stably expressing Nav channels,
indicating the HEK cell is a valid expression system to charac-
terize Nav inhibition by CBD.
Mechanism of sodium-current inhibition by CBD
We found CBD to be highly lipid bound in a TRANSIL
brain–lipid binding assay (Table 1). This supported the possi-
bility that the observed effectsmight be due to alterations to the
biophysical properties of the membrane. However, consistent
with previous studies (38), we found that phenytoin, a well
established nonselective Nav blocker also had high lipid bind-
ing (98.5%; Table 1), and it is assumed that phenytoin’s efficacy
against seizures is via direct Nav channel pore block (39–41).
The reported brain exposure levels required for efficacy in
CBD inhibition of Nav currents
J. Biol. Chem. (2018) 293(43) 16546–16558 16553
 by guest on N
ovem
ber 8, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
rodent maximal electroshock seizure models were also compa-
rable between CBD and phenytoin, supporting the possibility
that CBD could at least in part mediate its efficacy through
sodium-channel inhibition (Table 1) (6, 39, 41–46). This simi-
larity in lipid binding, however, raises the question of why the
two compounds inhibit through different mechanisms. When
comparing other physicochemical properties between the
compounds, it is striking that the calculated LogD of CBD and
phenytoin are 6.6 and 0.7, respectively (ChEMBL accession
numbers CHEMBL190461 and CHEMBL16). In contrast to
TRANSIL, which measures lipid binding, the LogD is derived
bymeasuring the partitioning of smallmolecules between octa-
nol and water at pH 7.4 and depends on a variety of structural
interactions, including hydrogen bonds and van der Waals
interactions. However, because octanol is structurally different
from membrane phospholipid bilayers, which contain both
polar and nonpolarmoieties, it cannotmodel these interactions
well. Consequently, it is possible for compounds to have similar
TRANSIL (lipid binding) numbers and different LogD, as found
for these compounds. This may suggest that despite having
similar lipid-binding percentages (Table 1), the much lower
LogD of phenytoin underlies its action as a classic sodium-
channel blocker that can enter the pore. In contrast, CBD’s very
high LogD could result in its accumulation deeper inside the
bilayer hydrophobic regions that leads to a greater effective
change in themembrane stiffness than phenytoin and underlies
CBD’s differentmode of current inhibition comparedwith phe-
nytoin. This disconnect between LogD and lipid-binding frac-
tions is further supported by considering another antiepileptic
sodium-channel pore blocker, carbamazepine, that has a lower
lipid-binding percentage (83.7%) than phenytoin, while having
a higher LogD (2.0) than phenytoin (Table 1) (ChEMBL acces-
sion number CHEMBL41543). We therefore suggest that
high lipid binding alone is not a sufficient property for a
compound to alter membrane stiffness, which results from a
combination of lipid binding with other physicochemical
properties unique to CBD over phenytoin and carbamaz-
epine. Overall, our results suggest that CBD has a nonselec-
tive inhibitory effect on voltage-dependent sodium currents.
The results presented in this study suggest that this mecha-
nism likely involves a combination of direct interactions
with channel hydrophobic regions, possibly the pore, and
changing the membrane bilayer flexibility through lipid
accumulation, as illustrated by the cartoon in Fig. 7C.
Results from previous studies along with our findings in this
study lead us to conclude that the underlying mechanism for
the reported efficacy of CBD against seizures likely involves
many systems beyond just CB receptors (7), G protein–coupled
receptors (50), or ion channels (10, 12). Dravet syndrome is
primarily caused by a heterozygous LOF of Nav1.1 in the brain
(51). As such, clinically used sodium-channel blockers are often
considered proconvulsant in Dravet syndrome (52, 53), pre-
sumably because they inhibit the reduced Nav1.1 current even
further. This raises the question of why CBD, as a nonselective
Nav inhibitor, would act as an anticonvulsant in Dravet syn-
drome. A recent study, however, unexpectedly demonstrated
efficacywith a nonselective sodium-channel blocker in aDravet
mouse model, suggesting that Nav inhibition can be protective
(54). In addition, another study in a Dravet mouse model sug-
gested that the efficacy ofCBDagainstDravet syndromemay be
mediated through antagonism at GPR55 receptors indepen-
dently of Nav channels (50).
The promiscuity of CBD interactions that have been
reported with multiple targets suggests that this compound,
like many natural products, is a pleiotropic compound with a
complex polypharmacology. It is therefore unlikely that any
efficacy against epilepsy is related solely to inhibitory effects on
Nav channels; however, our study suggests that inhibition of
Nav currents could occur at therapeutically relevant concentra-
tions and thus might contribute to efficacy against seizures.
Materials andmethods
Cell culture
Suspension HEK-293 cells were used for automated patch-
clamp experiments. HEK-293 cells were either stably trans-
fected using the inducible protein-expression T-RExTM system
or transiently transfected using Lipofectamine 2000 with
sodium -subunit cDNA constructs. The human SCN1B
cDNA construct was co-transfected into each cell line. The sta-
ble cell linesweremaintained underZeocin (5g/ml) andG418
(1 mg/ml) selection in Dulbecco’s modified Eagle’s medium,
10% fetal bovine serum, and 2 mM L-glutamine medium. The
hNav1.1 F1763A and the hNav1.6 N1768D mutations were
generated using the QuikChange site-directed mutagenesis kit
(Agilent Technologies). GABAergic iPSC neurons were pur-
chased from Cellular Dynamics International (Madison, WI).
The cells were seeded at 20–40% confluency onto glass cover-
slips and cultured up to 4 weeks according to user’s guide pro-
vided by the vendor. All cells were incubated at 37 °C/5% CO2.
All cell culture reagents were purchased from Thermo Fisher
Scientific (Waltham, MA) unless otherwise noted.
Automated patch-clamp
Automated patch-clamp recording was used for all experi-
ments unless otherwise noted. HEK cell lines stably expressing
the full-length cDNAs coding each Nav -subunit were gener-
ated. The human 1-subunit was co-expressed in each of inter-
nally generated cell lines. GenBankTM accession numbers
for -subunits were: human Nav1.1, NM_006920; hNav1.2,
NM_021007; hNav1.3, AF225987; hNav1.4, NM_000334;
hNav1.5, AC137587, SCN5A; hNav1.6, NM_014191; mNav1.6,
NM_ 001077499; and hNav1.7, NM_002977. Sodium currents
were measured in the whole-cell configuration using a Qube-
384 (Sophion A/S, Copenhagen, Denmark) automated voltage-
clamp system. To determine inhibition of the inactivated state,
the membrane potential was maintained at a holding potential
Table 1
The comparison of CBD to phenytoin and carbamazepine
Parameter Cannabidiol Phenytoin Carbamazepine
Brain–lipid binding–TRANSIL (%) 99.6 98.5 83.7
Plasma–protein binding (%) 95–99a 95a 70a
IC50 on Nav channels (M) 1–4 10a 25a
ED50 MES (mg/kg) 120a 8.2–17.5a 7.5a
Efficacious plasma level (M) 6.4–8.3a 4–10a 5–12a
Brain concentration (M) 21.9a 86a 9.7a
Brain/IC50 (ratio) 5.5–21.9 8.6 0.4
a These parameters were taken from literature (5, 6, 39, 41–48, 57–59).
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in which inactivation of the channel subtype is complete. The
membrane holding voltages used for subtype selectivity exper-
imentswere60mV for hNav1.5 and hNav1.7 and45mV for
hNav1.1, hNav1.2, hNav1.3, hNav1.4, hNav1.6, and mNav1.6.
In the protocol used to assess inhibition for hNav1.5 and
hNav1.7, a brief hyperpolarization to a negative (Vhold150
mV) voltage for 20 ms was applied at 1 Hz to recover fast-
inactivated channels but not compound bound channels, and
then a 20-ms test pulse to 0 mV was applied to quantify the
fractional availability of channels. For hNav1.1, hNav1.2,
hNav1.3, hNav1.4, and hNav1.6, the recovery period was 60 ms
applied at a frequency of 0.05 Hz. Intracellular solution con-
tained 120 mM CsF, 10 mM NaCl, 2 mM MgCl2, 10 mM HEPES,
adjusted to pH 7.2 with CsOH. The extracellular recording
solution contained 145 mM NaCl, 3 mM KCl, 1 mM MgCl2, 1.5
mM CaCl2, 10 mM HEPES, adjusted to pH 7.4 with NaOH. For
some studies, a flipped Na gradient was used where the extra-
cellular solution contained 125 mM choline chloride, 1 mM
NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES/
NaOH, pH 7.4, and the intracellular solution contained 115mM
NaF, 15mMCsCl2, 5 mMCsF, 3mMNa2ATP, 0.3 mMNa2GTP,
2 mMMgCl2, 0.1 mM CaCl2, 10 mM EGTA, and 10 mMHEPES/
CsOH, pH 7.2. Liquid junction potentials calculated to be 7
mV were not adjusted for. The currents were low-pass-filtered
at 5 kHz and recorded at 25 kHz sampling frequency. Series
resistance compensationwas applied at 100%, and leak subtrac-
tion was enabled. The Qube-384 temperature controller was
used to manipulate recording chamber temperature for certain
experiments. The rest of the measurements were obtained at
room temperature, which corresponds to 27  2 °C at the
recording chamber.Appropriate filters for cellmembrane resis-
tance (typically500MOhm), series resistance (	10MOhm),
and Nav current magnitude (500 pA at a test pulse from a
resting holding potential of 120 mV) were routinely applied
to exclude poor quality cells. Vehicle (0.5% DMSO) controls
were run on each plate to enable correction for any compound-
independent decrease of currents over time. Baselines were
established after 20 min in vehicle. Fractional inhibition was
measured as current amplitude from baseline to maximal inhi-
bition after 20 min of exposure to test compound unless other-
wise noted. Maximal inhibition was established by application
of 300 nM tetrodotoxin to eachwell at the end of the experiment
apart from for Nav1.5, for which 30 M tetracaine was used.
Normalizedmean inhibition datawere fit to theHill–Langmuir
equation,
Y  
Ch/IC50
h  
Ch (Eq. 1)
to estimate the half-maximal inhibitory concentration (IC50
value), where Y is the normalized inhibition, C is the com-
pound concentration, IC50 is the concentration of test com-
pound to inhibit the currents 50%, and h is the Hill coeffi-
cient. Data analysis was performed using Analyzer (Sophion
A/S, Copenhagen, Denmark) and Prism (GraphPad Software
Inc., La Jolla, CA) software. The IC50 values on the Qube-384
automated voltage-clamp platform were generated fromHill
equation fits to pooled data at each concentration and so do
not have standard errors.
Manual patch-clamp
Whole-cell patch-clamp recordings were obtained using an
Axopatch 200B patch-clamp amplifier (Molecular Devices,
Sunnyvale, CA) controlled and recorded using pClamp8
(Molecular Devices). The recording pipette intracellular solu-
tion contained 120 mM CsF, 10 mM NaCl, 2 mM MgCl2, 10 mM
HEPES, adjusted to pH 7.2with CsOH. Pipette resistances were
2–5 MOhm. The extracellular recording solution contained
145 mM NaCl, 3 mM KCl, 1 mM MgCl2, 1.5 mM CaCl2, 10 mM
HEPES, adjusted to pH 7.4 with NaOH. Currents were low-
pass-filtered at 5 kHz and recorded at 25 kHz sampling fre-
quency using a Digidata1440 (Molecular Devices). Series resis-
tance compensation was applied at 60–80%. The experiments
were performed at room temperature 19–20 °C. Liquid junc-
tion potentials calculated to be7 mV were not adjusted for.
Compound preparation
CBDwas purchased from Cayman Chemicals, and THCwas
purchased from Toronto Research Chemicals in powder form.
Powdered CBD and THC were dissolved in 100% DMSO to
create stock. The stock was used to prepare drug solutions in
extracellular solutions at various concentrations with no more
than 0.5% total DMSO content.
Manual patch-clamp IC50measurements
IC50 measurements were made while holding the membrane
voltage at45 mV. To activate sodium channels, a 60-ms pre-
pulse to150mVwas used to recover channels from fast inac-
tivation, followed by a 10-ms pulse to 20 mV to open the
channel. Using this protocol at a 1-Hz pulse rate, themembrane
voltage is maintained at45 mV 97% of the time. The peak of
the inward sodium current at 20 mV was measured, and a
stable baseline was established prior to perfusion with com-
pound, after which increasing concentrations of compound
were perfused, and the resulting currents were measured after
equilibrium was obtained.
Activation protocols
To determine the voltage dependence of activation, we mea-
sured the peak current amplitude at test pulse potentials rang-
ing from100mV to80mV in increments of5mV for 100
ms. Channel conductance (G) was calculated from peak INa,
GNa INa/V ENa (Eq. 2)
where GNa is conductance, INa is the peak sodium current in
response to the command potential V, and ENa is the Nernst
equilibrium potential. The calculated values for conductance
were fit with the Boltzmann equation,
G/Gmax 1/1 exp
V1/ 2 Vm/k (Eq. 3)
whereG/Gmax is normalized conductance amplitude, Vm is the
command potential, V1⁄2 is the midpoint voltage, and k is the
slope.
Steady-state fast-inactivation protocols
The voltage dependence of fast inactivationwasmeasured by
preconditioning the channels from120 to10 mV in incre-
CBD inhibition of Nav currents
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ments of 5mV for 100ms, followed by a 10-ms test pulse during
which the voltage was stepped to20mV. Normalized current
amplitudes from the test pulse were fit as a function of voltage
using the Boltzmann equation,
I/Imax  1/(1 exp[V1/ 2 Vm]k) (Eq. 4)
where Imax is the maximum test pulse current amplitude.
State dependence protocols
To determine state dependence, potencywasmeasured from
four different holding potentials (100, 90, 80, and 70
mV). The protocol startedwith a holding potential of100mV
followed by 180 20-ms depolarizing pulses to 0 mV at 1 Hz.
Then the holding potential was depolarized by 10 mV, and the
180-pulse protocol was repeated until70 mV was reached.
Recovery from inactivation protocols
Recovery from inactivation was measured by holding the
channels at120mV, followed by a depolarizing pulse to 0mV,
and then the potential was returned to 120 mV. This was
followed by a depolarizing 10-ms test pulse to 0mV tomeasure
availability. Recovery from inactivationwasmeasured after pre-
pulse durations of 300 ms and 10 s and fit with a biexponential
function of the form,
SpanFast  (Y0  Plateau)  PercentFast  0.01 (Eq. 5)
SpanSlow  (Y0  Plateau)  (100 PercentFast)  0.01
(Eq. 6)
Y  Plateau SpanFast  exp(KFast  t)
 SpanSlow  exp(KSlow  t) (Eq. 7)
where t is time in seconds,Y0 is the y intercept at t 0,KFast and
KSlow are rate constants in units the reciprocal of t, and Percent-
Fast is the fraction of the Y signal attributed to the fast decaying
component of the fit.
Kinetics at varying temperatures
The kinetics of CBD block were measured at three tempera-
tures: 20, 28, and 33 °C. The channels were held at 45 mV
followed by a recovery pulse to 150 mV for 60 ms. The
blocked sodium current was normalized to vehicle and subse-
quently fit with a single exponential function.
Y  Y0  Plateau)  exp(K  t  Plateau (Eq. 8)
Action-potential modeling
Neuronal action-potentialmodelingwas based on amodified
Hodgkin–Huxley model (30). The model was modified to
match the properties of cortical pyramidal cells (31). The mod-
ified parameters were based on electrophysiological results
obtained from whole-cell patch-clamp experiments in this
study. Themodel accounted for activation voltage dependence,
steady-state fast-inactivation voltage dependence, and peak
sodium currents.
Homologymodeling
Homology modeling was performed using the Swiss-Model
server. The cryo-EM sodium channel structure of Navpas was
used as a template against which the hNav1.1 sequence was
modeled (55, 56).Modeling was done according to the protocol
established by Bordeli et al. (49).
Molecular docking
The homology model of hNav1.1 and SMILES structure of
CBD were imported into Chimera. The structures were ener-
getically minimized, and the lowest energy structure was deter-
mined as the most likely molecular interaction.
Immunocytochemistry
HEK cells stably transfected with the 1-subunit and
hNav1.1 -subunits were incubated for 24 h with 0 (vehicle)
and 5MCBD.After this incubation period, the cells were fixed
in 4% paraformaldehyde for 10 min while being incubated on a
shaker. Then cells were incubated in 0.1% Triton X-100 for a
further 10 min. The cells were blocked in 10% goat serum for
30–45 min. Following this step, diluted primary anti-hNav1.1
(1:100, mouse monoclonal IgG, commercially available via UC
Davis/NIH NeuroMab Facility) antibodies were added. The
next day, the cells were incubated in PBS for 10 min. Lastly,
secondary Alexa Fluor 546 IgG (1:500) and Hoe33342 (nuclear
stain) were added. Stained cells were studied using a Nikon
confocal microscope. Images were analyzed using ImageJ.
Lipid-binding assessment
Made using the TRANSILXL brain absorption kit (ADME
Cell) as per the manufacturer’s instructions.
Statistics
A one-factor analysis of variance was used to compare the
mean responses. Post hoc tests using the Tukey Kramer adjust-
ment compared the mean responses between channel variants
across conditions. A level of significance   0.05 was used in
all overall post hoc tests, and effects with p values less than 0.05
were considered to be statistically significant. All values are
reported as means S.E. for n cells.
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